Abstract 850P
Background
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults. The origin can be found in chromosomal translocations as well as in accumulated mutations in genes involved in hematopoietic proliferation and differentiation. Despite being considered a heterogeneous malignancy, AML possesses many genetic aberrations, including the overexpression of MYC and the downregulation of PP2A, both essential regulators of cell proliferation, apoptosis, and differentiation, and they, directly and indirectly, regulate each other’s activity. We have generated a zebrafish model of MYC-driven AML to rapidly test the effects of different drugs in tumor development.
Methods
After the generation of a transgenic zebrafish line expressing the human MYC under the control of the neutrophils-specific promoter lysozyme (lyz:hMYC), we checked the expansion of neutrophils in whole larvae and the colonization of the adult hematopoietic organ. We investigated the effects of chemical manipulation of PP2A activity on neutrophil expansion and on MYC phosphorylation and degradation. Single-cell RNA sequencing analysis has been performed to shed light into the mechanisms of PP2A/proteasomal-mediated degradation of oncogenic MYC in AML.
Results
In vivo imaging of whole larvae revealed a robust expansion of neutrophils in zebrafish larvae which expressed MYC from 3 to 8 days post-fertilization (dpf). Surprisingly, the neutrophil number gradually returned to normal levels from 10 dpf onwards, coinciding with degradation of MYC. Pharmacological inhibition of the proteasome resulted in the stabilization of MYC protein and further expansion of transformed neutrophils. Similarly, inhibition of PP2A phenocopied the effects of proteasome inhibition. Otherwise, pharmacological activation of PP2A prevented neutrophil expansion and increased phosphorylation of S62 and T58 of MYC, suggesting a critical role PP2A in MYC proteasomal degradation.
Conclusions
Our results show that PP2A critically regulates MYC degradation in neutrophils preventing their oncogenic transformation. In addition, the zebrafish model of AML is a unique tool for chemical screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Murcia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18